BAGNEUX, France–(BUSINESS WIRE)–Regulatory News:
GENOMIC VISION (Paris:GV) (FR0011799907 – GV), a biotechnology company that develops diagnostic tools and services dedicated to the analysis and control of changes in the genome, is pleased to announce the signature of a contract with Toda Pharma for the distribution of their Covid-19 rapid diagnostic orientation tests: Toda Coronadiag+ and Coronadiag AG. Toda Pharma is a French pharmaceutical company specialising in rapid diagnostic tests that markets a wide range of products for healthcare professionals.
Through this distribution agreement, Genomic Vision intends to offer a complete solution to facilitate the diagnosis of the Covid-19, and thus fluidify the screening effort at the level of laboratories that are currently very much in demand. With 15 years of expertise in the field of medical devices and in-vitro diagnostics, Genomic Vision has carefully selected these tests developed by Toda Pharma for their performance and the information they provide:
- the Coronadiag Ag test allows the antigenic detection of coronavirus from nasopharyngeal or oropharyngeal samples, thus offering an alternative to the commonly used PCR test. The test proved to be effective 1-7 days after the onset of symptoms or after the suspected infection.
- the Coronadiag+ test detects IgG and IgM immunoglobulins from blood and it proved to be effective 14-19 days after a suspected infection. Furthermore, it has been validated by the National Reference Centre (CNR), Institut Pasteur and the Frech Ministry of Solidarity and Health.
These two tests in kit form increase the probability of detecting individuals infected with SARS-CoV-2. Their use does not require any additional specific instrumentation and provides results in 15 minutes, thus considerably increasing the number of tests carried out.
Genomic Vision therefore chooses to distribute a complete, reliable and rapid solution to facilitate the screening of Covid-19, and is thus committed to the effective fight against this pandemic.
Thanks to its network of hospital partners and its expertise in in-vitro diagnostic devices, Genomic Vision has considerable assets to meet national and international demand and thus contribute to the wide distribution of these tests.
Aaron Bensimon, CSO and founder of Genomic Vision, explains: “In addition to our core business, which is based on the numerous applications offered by molecular combing technology, we are very proud to be contributing to the management of the current health crisis. Thanks to our strong network of hospital partners, we intend to accelerate the commercialization of Covid-19 rapid diagnostic orientation tests manufactured by Toda Pharma, a major French player in diagnostics.”
Yossi Berros, CEO of Toda Pharma, adds: “Toda Pharma was one of the first European laboratories to develop as early as February 2020 a rapid serological test for the detection of coronavirus IgG IgM. With our new antigenic diagnostic test, we aim to offer short and long-term patient screening. Genomic Vision is the ideal partner to make this complete solution available to as many people as possible, and is committed to working with us to ensure better health prevention for everyone”.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of the CAC® Mid & Small and CAC® All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the reference document dated March 29, 2019 filed with the AMF under reference number R19-004, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.